Evidence map›Paper›PMID 28188308›Full record

ArticleOncotarget2017

Tetraspanin 8 is a novel regulator of ILK-driven β1 integrin adhesion and signaling in invasive melanoma cells.

Manale El Kharbili, Clément Robert, Tiffany Witkowski, Emmanuelle Danty-Berger, Laetitia Barbollat-Boutrand, Ingrid Masse, Nicolas Gadot, Arnaud de la Fouchardière, Paul C McDonald, Shoukat Dedhar and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. The Genetics of Acne.Annals of human genetics · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Homeostasis, regeneration and tumour formation in the mammalian epidermis.The International journal of developmental biology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Manale El KharbiliUniversité de Lyon, Lyon, France.
Clément RobertUniversité de Lyon, Lyon, France.
Tiffany WitkowskiClermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France.
Emmanuelle Danty-BergerLaboratoire CarMeN (INSERM 1060, INRA1397, INSA), Université Lyon 1, Lyon, France.
Laetitia Barbollat-BoutrandUniversité de Lyon, Lyon, France.
Ingrid MasseUniversité de Lyon, Lyon, France.
Nicolas GadotUniversité Lyon 1, Fédération de Recherche Santé Lyon-Est, ANIPATH, Faculté Laennec, Lyon, France.
Arnaud de la FouchardièreDépartement de Biopathologie, Centre Léon Bérard, Lyon, France.
Paul C McDonaldDepartment of Integrative Oncology, British Columbia Cancer Research Center, Vancouver, Canada.
Shoukat DedharDepartment of Integrative Oncology, British Columbia Cancer Research Center, Vancouver, Canada.
François Le NaourINSERM U602, Villejuif, France.
Françoise DegoulClermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France.
Odile Berthier-VergnesUniversité de Lyon, Lyon, France.
Centre National de la Recherche Scientifique · FRUniversité Claude Bernard Lyon 1 · FRCentre Léon Bérard · FRHôpital Paul-Brousse · FRInserm · FRLaboratoire CarMeN · FRUniversité Clermont Auvergne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is well known for its propensity for lethal metastasis and resistance to most current therapies. Tumor progression and drug resistance depend to a large extent on the interplay between tumor cells and the surrounding matrix. We previously identified Tetraspanin 8 (Tspan8) as a critical mediator of melanoma invasion, whose expression is absent in healthy skin. The present study investigated whether Tspan8 may influence cell-matrix anchorage and regulate downstream molecular pathways leading to an aggressive behavior. Using silencing and ectopic expression strategies, we showed that Tspan8-mediated invasion of melanoma cells resulted from defects in cell-matrix anchorage by interacting with β1 integrins and by interfering with their clustering, without affecting their surface or global expression levels. These effects were associated with impaired phosphorylation of integrin-linked kinase (ILK) and its downstream target Akt-S473, but not FAK. Specific blockade of Akt or ILK activity strongly affected cell-matrix adhesion. Moreover, expression of a dominant-negative form of ILK reduced β1 integrin clustering and cell-matrix adhesion. Finally, we observed a tumor-promoting effect of Tspan8 in vivo and a mutually exclusive expression pattern between Tspan8 and phosphorylated ILK in melanoma xenografts and human melanocytic lesions. Altogether, the in vitro, in vivo and in situ data highlight a novel regulatory role for Tspan8 in melanoma progression by modulating cell-matrix interactions through β1 integrin-ILK axis and establish Tspan8 as a negative regulator of ILK activity. These findings emphasize the importance of targeting Tspan8 as a means of switching from low- to firm-adhesive states, mandatory to prevent tumor dissemination.

Indexed as

AnimalsBlotting, WesternCell AdhesionCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansIntegrin beta1MaleMelanomaMice, NudeMicroscopy, ConfocalMutationNeoplasm InvasivenessPhosphorylationProtein Serine-Threonine KinasesIntegrin beta1Protein Serine-Threonine KinasesProto-Oncogene Proteins c-aktScaffold Protein ILKTetraspaninsTSPAN8 protein, humanILKintegrinmatrixmelanomatetraspanin 8

Identifiers

PMID28188308
PMCPMC5370029
OpenAlexW2584999205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.